Clinical Trials Logo

Carcinoma, Ductal clinical trials

View clinical trials related to Carcinoma, Ductal.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03819088 Not yet recruiting - Gastric Carcinoma Clinical Trials

Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

This randomized study examines how well zinc works in improving quality of life in patients with gastrointestinal cancer that cannot be removed by surgery who are receiving chemotherapy. Zinc may help to improve patient's quality of life by preventing zinc deficiency.

NCT ID: NCT03775213 Not yet recruiting - Clinical trials for Ductal Carcinoma in Situ

Communication of Personalized Cancer Risk

Start date: February 28, 2019
Phase: N/A
Study type: Interventional

The purpose of this research study is to develop a personalized decision support tool that will maximize informed decision-making and minimize overtreatment in patients diagnosed with ductal carcinoma in situ (DCIS).

NCT ID: NCT03749850 Not yet recruiting - Breast Cancer Clinical Trials

Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer

Start date: April 2019
Phase: Phase 1
Study type: Interventional

In this phase I feasibility study, the investigators evaluate the combination of lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox) with local hyperthermia and cyclophosphamide (C), for the local treatment of the primary breast tumour in patients with metastatic breast cancer. When heated to 40-43 degrees Celsius (ºC), LTLD releases a very high concentration of doxorubicin locally within seconds. Hyperthermia of the primary tumour will be induced by Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) on a dedicated Sonalleve MR-HIFU breast system. The investigators hypothesize that by substituting doxorubicin (A) in the AC-chemotherapy regimen for the combination of LTLD and MR-HIFU induced hyperthermia, optimal local tumour control can be achieved without compromising systemic toxicity or efficacy. This will be the first study to evaluate LTLD with MR-HIFU hyperthermia in breast cancer patients.

NCT ID: NCT03614364 Not yet recruiting - Clinical trials for Salivary Duct Carcinoma

Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma

Start date: August 2018
Phase: Phase 2
Study type: Interventional

1. Study outline This is a multicenter, single-arm, phase II trial to evaluate the efficacy and safety of nanoxel plus herzuma combination chemotherapy in patients with metastatic salivary ductal cancer. Approximately 41 patients will be enrolled. Treatment will be continued until disease progression or unacceptable toxicities. Response evaluation will be performed every 2 cycles. 2. Dosing & Treatment schedule D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks (In case of discontinuation of nanoxel without progression, single agent herzuma can be administered until progression)

NCT ID: NCT03437915 Not yet recruiting - Breast Cancer Clinical Trials


Start date: March 2019
Phase: N/A
Study type: Interventional

Partial breast irradiation is typically performed after surgical removal of the tumor. Partial breast irradiation allows for focused radiation to the area from which the cancer was removed, sparing breast tissue from the potential bad effects of radiation compared to radiating the whole breast, which was the standard of care for many years. This study is evaluating the use of partial breast irradiation with NIBB performed before surgery instead of after surgery.This should allow researchers to target the cancer even more accurately and result in less normal breast tissue receiving radiation which may cause less side effects and/or a better cosmetic outcome. In this study partial breast treatment will be given with NIBB in 5 treatments over about 1 week. Surgical removal of the tumor will then be performed between 4-12 weeks following radiation treatment. Researchers believe that participant's risk of complications from surgery will not be higher after getting these radiation treatments than it would have been if participants had surgery first, but that is one of the things researchers are studying.